Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy) (Immuno-ab)

Checkmab S.r.l.

Status: Enrolling

Conditions: Healthy Donors

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06842407

ID3411

Details and patient eligibility

About

The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• blood donors
• age of 18 years or more
• able to sign informed consent

Exclusion criteria

• age below 18 years
• Positive for HIV, HCV, HBV
• not suitable for blood donation
• not able to understand or sign informed consent

Trial design

600 participants in 1 patient group

Healthy Donors

Description:

subjects over 18 years of age